Partner at GSR Ventures Dr. Sunny Kumar, talks about priorities, interest areas, investing and the distinction between tech-enabled and tech services.

The Centers for Medicare and Medicaid Services is not reconsidering the national coverage determination for Food and Drug Administration (FDA)-approved medications for Alzheimer’s disease. The FDA-approved monoclonal antibodies are directed against amyloid, or the protein buildup, for the treatment of Alzheimer’s disease. 

Surgical procedures at in-network hospitals carry a far higher cost than at independent hospitals, a trend that held true for 15 of 16 surgical procedures analyzed in a new study published in JAMA Network Open.